Protagonist Therapeutics, Inc. (PTGX)
$138.49-4.41%Close
SELLRECOVERY · day 3
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $8.9B
- Beta
- 1.79
- P/E (TTM)
- 113.69
- Short % float
- 17.80%
- Days to cover
- 11.5
- SI change
- +14.8%
- 1W
- -0.14%
- 1M
- -6.29%
- vs SPY 1W
- -0.01%
- vs SPY 1M
- -8.79%
Industry peers
FMP comparable companies · ranked by market cap
- SYRESELLSpyre Therapeutics, Inc.$7.0BCRISISQ 9$80.11-6.34%
- IMVTSELLImmunovant, Inc.$6.6BCRISISQ 25$32.11-2.61%
- IRONSELLDisc Medicine, Inc.$2.4BCRISISQ 0$61.65-6.42%
- ANABSELLAnaptysBio, Inc.$1.4BCRISISQ 25$47.89-0.98%
- ODTXSELLOdyssey Therapeutics, Inc.$871MQ 19$18.13-5.59%
- ACRSSELLAclaris Therapeutics, Inc.$517MCRISISQ 9$3.70-3.61%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on PTGX?
- LOPJLB’s latest quantitative signal on Protagonist Therapeutics, Inc. (PTGX) is SELL in a RECOVERY regime. Signals are updated daily.
- What market regime is PTGX in?
- Protagonist Therapeutics, Inc. (PTGX) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Protagonist Therapeutics, Inc. (PTGX) do?
- Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials f…